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Abstract
Background: The lack of axonal regeneration in the central nervous system is attributed among other factors to the
formation of a glial scar. This cellular structure is mainly composed of reactive astrocytes that overexpress two intermediate
filament proteins, the glial fibrillary acidic protein (GFAP) and vimentin. Indeed, in vitro, astrocytes lacking GFAP or both
GFAP and vimentin were shown to be the substrate for increased neuronal plasticity. Moreover, double knockout mice
lacking both GFAP and vimentin presented lower levels of glial reactivity in vivo, significant axonal regrowth and improved
functional recovery in comparison with wild-type mice after spinal cord hemisection. From these results, our objective was
to develop a novel therapeutic strategy for axonal regeneration, based on the targeted suppression of astroglial reactivity
and scarring by lentiviral-mediated RNA-interference (RNAi).
Methods and Findings: In this study, we constructed two lentiviral vectors, Lv-shGFAP and Lv-shVIM, which allow efficient
and stable RNAi-mediated silencing of endogenous GFAP or vimentin in vitro. In cultured cortical and spinal reactive
astrocytes, the use of these vectors resulted in a specific, stable and highly significant decrease in the corresponding protein
levels. In a second model — scratched primary cultured astrocytes — Lv-shGFAP, alone or associated with Lv-shVIM,
decreased astrocytic reactivity and glial scarring. Finally, in a heterotopic coculture model, cortical neurons displayed higher
survival rates and increased neurite growth when cultured with astrocytes in which GFAP and vimentin had been
invalidated by lentiviral-mediated RNAi.
Conclusions: Lentiviral-mediated knockdown of GFAP and vimentin in astrocytes show that GFAP is a key target for
modulating reactive gliosis and monitoring neuron/glia interactions. Thus, manipulation of reactive astrocytes with the Lv-
shGFAP vector constitutes a promising therapeutic strategy for increasing glial permissiveness and permitting axonal
regeneration after central nervous system lesions.
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Introduction
Astrocytes are essential companions of neurons from early stage
of the central nervous system (CNS) formation. As radial glial cells,
they support neuronal migration [1]. At adult stages, they have
major functions in neuronal homeostasis [2,3], formation and
maintenance of the blood-brain barrier [4], control of synaptic
communication or immune response modulation [5,6,7,8]. In the
injured CNS, reactive astrocytes undergo important morpholog-
ical modifications, such as hyperplasia and hypertrophy [9,10],
and express a broad range of molecules with growth inhibitory
properties, such as chondroitin sulfate proteoglycans and tenascin-
C [11,12,13,14,15]. Thus reactive astrocytes among other cell
types such as microglial cells, oligodendrocytes precursors,
Schwann cells or fibroblasts, are mainly involved in the formation
of both a physical and a biochemical barrier to axonal
regeneration: the glial scar [10,16].
The main molecular hallmark of reactive astrocytes is the
upregulation of two intermediate filament (IF) proteins, the glial
fibrillary acidic protein (GFAP) and vimentin, which are the major
components of astrocytes cytoskeleton [17,18,19]. The expression of
these two proteins is tightly regulated during the development and is
associated with the astrocytic differentiation [20,21]. At adult stages
the exact physiological roles of the GFAP and vimentin in the
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astrocytes remain incompletely understood, but they appear to be
involved in the maintenance of shape, mechanical stability, or in the
vesicle mobility in astrocytes [22,23,24]. Physiologically, GFAP is
also necessary for the integrity of the blood-brain barrier [25,26],
the maintenance of CNS cytoarchitecture [25,27], and of synaptic
function [28]. After CNS injury, the upregulation of both GFAP
and vimentin expression during astrogliosis play a major role in
astrocytic motility [29] and hypertrophy [17,30], which are key
properties of reactive astrocytes contributing to the glial scar [16]. It
has been therefore suggested that the overproduction of GFAP and
vimentin after CNS lesions could be used as a specific target for
neuronal repair strategies.
A series of experiments with mutant mice lacking GFAP and
vimentin have demonstrated the consequences of the absence of
both proteins on astrocytes reactivity and axonal plasticity in vitro
and in vivo. Survival of cortical neurons and neurite outgrowth was
improved in cocultures with GFAP2/2 or GFAP2/2Vim2/2
spinal astrocytes [31]. In vivo, double knockout mice lacking GFAP
and vimentin presented lower than normal levels of astroglial
activity, with a reduced astrocytic hypertrophy and a defective scar
formation [30,32,33]. Moreover GFAP 2/2 Vim 2/2 mice
showed significant axonal regrowth of the descending fibers of the
corticospinal tract (CST) and ventral horn serotonergic tract,
associated with an improved functional recovery after spinal cord
hemisection [32]. These mice also presented improved axonal
regeneration after lesion of entorhinal cortex [30]. However, no
CNS repair strategies based solely on the manipulation of the
astrogliosis have yet been developed. The modulation of astrogliosis
through posttranscriptional inhibition of GFAP and vimentin
production may provide a promising new strategy with potential
clinical applications for promoting axonal regeneration after
formation of a CNS lesion.
Long-term, stable inhibition of the expression of single genes has
been successfully achieved in mammalian cells, using lentiviral
vectors mediating the constitutive expression of short-hairpin
RNAs (shRNAs), which are rapidly cleaved into small-interfering
RNAs (siRNAs) in situ [34,35]. Thus, RNA-interference (RNAi)
appears to be a remarkable tool with potential applications for use
in clinical practice, for the treatment of diseases caused by a
defective gene, which needs to be inhibited. In this study, we
aimed at silencing the expression of the GFAP and vimentin genes
through a lentiviral-mediated RNAi approach, in order to reduce
astrogliosis in reactive astrocytes. We first identified target
sequences in the GFAP and vimentin mRNAs that might enable
us to decrease efficiently the levels of both proteins. We then
produced lentiviral vectors allowing constitutive expression of the
corresponding shRNA sequences. We show that these vectors
induced a strong, stable decrease in endogenous GFAP and
vimentin expression in primary cultured astrocytes. These vectors
also improve neuronal survival and neurite outgrowth and prevent
glial scarring in an in vitro model using scratched astrocytes.
Materials and Methods
Ethical Statements
All animals were handled in strict accordance with good animal
practice as defined by the French animal welfare bodies, and all
animal work was approved by the Direction De´partmentale des
Services Ve´te´rinaires de Paris and by the Direction De´partemen-
tale des Services Ve´te´rinaires de l’He´rault.
Plasmid construction
All the primers used in this study were synthesized by
Eurogentech, (Angers, France) and all the restriction enzymes were
produced by New England Biolabs (Ipswich, MA). We first
constructed plasmids encoding mouse GFAP and/or mouse
vimentin fused to the Enhanced Green Fluorescent Protein (EGFP).
The murine GFAP and vimentin cDNA sequences were obtained
by RT-PCR, using the following primers: 59-GGGAATT-
CATGCCTCCGAGACGGTGGTC-39 (GFAP sense strand), 59-
GCGATCCATCACCACGTCCTTGTGCTC-39 (GFAP anti-
sense strand), 59-GCGAATTCCAAGCCAGCCCACCTTCGA-
39 (vimentin sense strand) and 59-GCGGATCCAGTTCAAGGT-
CATCGTGATGCTG-39 (vimentin antisense strand). The murine
GFAP and vimentin cDNAs were then inserted between the EcoRI
and BamHI restriction sites in pEGFP-N1 (Clontech, Mountain
View, CA).
We designed 66-nucleotide potential shRNA sequences to
silence the expression of the mouse GFAP or vimentin genes in a
specific manner as previously described (Rubinson 2003). Each
shRNA sequence comprises a selected siRNA sequence targeting
the murine GFAP mRNA (NCBI Accession Number
NM_010277) or murine vimentin mRNA (NCBI Acession
Number NM_011701) in both sense and antisense orientations,
separated by a 9 nucleotides loop (59-TTCAAGAGA-39) and
followed by five thymidine residues as an RNA polymerase III
transcription termination signal. BbsI and BamHI restriction sites
were incorporated at the 59 and 39 ends, respectively. Potential
siRNA sequences were selected empirically, as described by
Tuschl et al., and with the help of the Qiagen siRNA design tool
(Qiagen, Valencia, CA; http://www.biopredsi.org/design.html)
and the Whitehead Institute for Biomedical Research (http://jura.
wi.mit.edu/bioc/siRNAext/), [36]. The DNA fragment encoding
each shRNA was generated by annealing two complementary
oligonucleotides (Eurogentech) and the resulting double-stranded
DNA fragments were inserted between the BbsI and BamHI sites of
pcDNA-DU6wt. We obtained pcDNA-DU6wt from pcDNA3.0,
by replacing the original CMV promoter with the U6 promoter,
which was obtained by RT-PCR from HEK 293-T cells.
For the production of lentiviral vectors, cassettes allowing
effective shGFAP or shVIM expression under control of the U6
promoter were recovered from the pcDNA-DU6wt-shRNA and
inserted into the lentivector precursor plasmid pFlap-PGK-EGFP-
WPRE. This plasmid is a derivative of pTrip-CMVmin-WPRE, as
described by Vogel et al. [37], from which the CMVmin element has
been deleted [38]. This element was removed by BamHI-KpnI
digestion and replaced by a multicloning site (MCS) containing
single restriction sites for SalI and NheI. The PGK sequence was
amplified by PCR from pTrip-PGK-EGFP, with primers incorpo-
rating a BamHI restriction site 59 to the PGK gene (59-CGG-
GATCCTGCTCGAGTATTCTACCGGGTAGGGGAGGCG-
39) and a SalI restriction site 39 to the gene (59-GCTGGGT-
CGACTCGAAAGGCCCGGAGATGAGG-39). The EGFP cod-
ing sequence was amplified by PCR from pEGFP-N1 (Clontech),
with primers incorporating a SalI restriction site 59 to the gene (59-
GTGGGTCGACCTCGCCACCATGGTGAGCAAGGGC-39)
and an XbaI restriction site 39 to the gene (59-GCTCTAGAAGC-
TAGAGTCCGGCCGCTTTACTTGTAC-39). The WPRE se-
quence was amplified by PCR from pTrip-U6min-shGFP-WPRE,
with primers incorporating an XbaI restriction site 59 to the gene (59-
GCGGATCCATGTCGACGTAGCTAGCGATAATCAACCT-
CTGGATTACAAAATTTGTG-39) and a KpnI restriction site 39 to
the gene (59-GGGGTACCATCCGATGCGGGGAGGCGGC-39).
The various PCR products were sequentially subcloned into pTrip-
U6min-shGFP-MCS, using the appropriate restriction sites.
Finally, the U6-shGFAP or U6-shVIM cassette was inserted into
pFlap-PGK-EGFP-WPRE between the MluI and BamHI restriction
sites.
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As controls, a lentiviral vector expressing only EGFP under
control of the PGK promoter, a lentiviral vector producing a
‘‘scrambled’’ shRNA sequence, and a lentiviral vector producing a
shRNA directed against the OB-RGRP transcript and previously
described (Couturier et al. 2007) were produced.
HEK-293T cell line culture, transfection and lentivirus
production
HEK 293 T cell culture. The HEK-293T cell line (ATCC #
CRL-11268) was cultured at 37uC, under a humidified 5% CO2/
95% air atmosphere, in Dulbecco’s modified Eagle medium
(DMEM, Invitrogen, Carlsbad, CA) supplemented with 10% fetal
bovine serum (FBS, Invitrogen) and 1% antibiotic solution
(mixture of 10 U/ml penicillin G and 10 mg/ml streptomycin,
Eurobio, Courtaboeuf, France).
Transient transfection of HEK 293 T cells for shRNA
screening. HEK 293 T cells were plated in 40 mm dishes and
transfected with a total of 4 mg of DNA per dish, using the calcium
phosphate method. For each transfection, the molar ratio of
plasmid encoding fusion protein construct/plasmids encoding
shRNAs was 1:20. Culture medium was removed six hours after
transfection and replaced with fresh medium. Cells were fixed in
4% paraformaldehyde (PFA) in PBS, 72 hours after cotransfection
and EGFP levels were analyzed with a FACScan flow cytometer
(Becton Dickinson, Franklin Lake, NJ). Results were given as mean
percentages6SEM. Statistical comparisons were done using
paired T-test. Significance was accepted at p,0.05.
Lentiviral vector production. Lentiviral vector particles
were produced by the calcium phosphate cotransfection method,
as previously described [39,40]. Cells were cotransfected with the
vector plasmid, an encapsidation plasmid (p8.9) [41], and a
plasmid encoding the vesicular stomatitis virus envelope
glycoprotein (pMD-G), in a culture medium containing
chloroquine (2,5 mM, Sigma-Aldrich). The medium was replaced
6 hours after transfection and collected 36 hours later.
Supernatants were treated with DNAse I (Roche) and subjected
to ultracentrifugation at 22 000 rpm (rotor SW28, Beckman-
Coulter) for 90 minutes. The resulting pellet was resuspended in
0.1 M PBS, aliquoted and frozen at 280uC until use.
The HIV p24 gag antigen was quantified for each stock by
ELISA (HIV-1 P24 antigen assay, Beckman Coulter, Fullerton,
CA). EGFP-expressing vectors were titrated by transducing 100
000 HEK 293 T cells in 24-well plates with a serial dilution (4 ml,
461021 ml, 461022 ml, 461023 ml, 461024 ml, 461025 ml). Cells
were harvested by centrifugation and resuspended in a fixative
solution of 1% PFA, 72 hours after transduction. The number of
EGFP-positive cells was determined in a FACScan flow cytometer
(Beckton Dickinson).
Primary glial cell line cultures and lentiviral transductions
Glial cell culture. Primary cultures of glial cells were
established from the spinal cord (SC) or cortices of two-day-old
C57/Bl6 mice (Janvier, Le Genest-St-Isle, France). The animals
were sacrificed in aseptic conditions. The SC and cerebral cortices
were dissected, freed from meninges and collected in cold HBSS
supplemented with calcium and magnesium (Invitrogen), glucose
(6 g/L) and 1% antibiotic solution (Invitrogen). The fragments of
SC and cortex were then treated with 0.25% trypsin-EDTA
(Eurobio) and DNAse A (50 mg/ml, Roche, Neuilly-sur-Seine,
France) for 8 minutes at 37uC. Trypsin was then inactivated by
adding 10% FBS. Tissues were rinsed in HBSS without calcium and
magnesium (Invitrogen) and resuspended in 1 ml of culture medium
consisting of a 1:1 mixture of DMEM and Ham’s F12 medium
(DMEM/F12 1:1, Invitrogen) supplemented with 10% FBS,
glucose (6 g/L) and antibiotics. Cells were mechanically
dissociated, resuspended in the same culture medium and plated
at a final concentration of ,200 000 cells/well on glass coverslips
treated with 50 mg/ml of low-molecular weight poly-D-lysine
(Sigma-Aldrich, St Louis, MO) in 24-well dishes (Nunc, Roskilde,
Danemark), for immunocytochemical analyses. For
immunoblotting studies, cells were plated in six-well dishes (TPP,
Trasadingen, Swizerland), with one cortical hemisphere per well, or
one spinal cord per well. The culture medium was completely
replaced by fresh cold medium after 24 hours and weekly thereafter.
In vitro transduction of glial cells. One week after seeding,
glial cells were transduced with the lentiviral vectors. The medium
was removed and replaced with lentiviral vector diluted in
DMEM/F12 medium without FBS but with antibiotics. Cells
were incubated overnight with this lentiviral vector-medium
mixture (500 ml/well for 24-well plates and 1 ml/well for 6-well
plates). After 24 hours, the infection medium was removed and
replaced with fresh DMEM/F12 medium supplemented with
FBS. The amount of lentiviral vector applied to the cells is
expressed as a multiplicity of infection (MOI), corresponding to
the number of transducing particles (TU) per cell.
Glial cell scratch wound assay
We used two different paradigms for the scratch wound assay. In
the first paradigm, confluent glial cell monolayers were scratched
with a sterile 20 to 200 mm plastic pipette tip (Corning, NY) two
weeks after lentiviral transduction. Cells were then washed twice
with PBS and the medium was replaced with fresh DMEM/F12
medium supplemented with glucose, FBS and antibiotics. Cells were
fixed with 4% paraformaldehyde (PFA, Sigma-Aldrich) in PBS after
48 hours, one week and two weeks of incubation.
In the second paradigm, confluent glial cell monolayers were first
scratched as described above, and the cells were then immediately
transduced with the lentiviral vectors. The medium was removed
24 hours after transduction and the cells were fixed in 4% PFA in
PBS 48 hours, one week and two weeks after scratching.
Western blot analysis
Proteins were extracted from glial cell cultures two weeks after
transduction, for western blotting. Glial cells were washed in PBS,
scraped from the dishes or plates into PBS and centrifuged at
1000 g for 10 minutes. The cell pellets were washed again,
resuspended in PBS and centrifuged at 4uC and at 10 000 g.
Proteins were extracted from the cell pellets in lysis buffer, as
previously described [42]. Protein concentration was determined
by the Bradford method. Equal loads of proteins (20 mg) were
subjected to electrophoresis in 9% polyacrylamide gels in the
presence of SDS and the resulting bands were blotted onto a
nitrocellulose membrane in transfer buffer at 50 mA overnight.
The membrane was blocked by incubation with 5% skimmed milk
in PBS-Tween 0.1% for 1 hour, and was then incubated with the
primary antibody — (1) rabbit polyclonal IgG directed against
GFAP (1:100 000, Dako, Glostrup, Denmark) or (2) mouse
monoclonal IgG directed against vimentin (RV202 clone, 1:1000,
BD-Pharmingen) — overnight at 4uC or for two hours at room
temperature. The membrane was then incubated with secondary
antibody: peroxidase-conjugated anti-rabbit (1:5000) or anti-
mouse (1:5000) IgG (Amersham). The binding of antibodies to
proteins was detected by enhanced chemiluminescence, using an
ECL detection kit for western blots (Amersham).
Immunocytochemical analysis of glial cell monocultures
Two or three weeks after transduction, the cells were fixed by
incubation in 4% PFA in PBS for 30 minutes to one hour at room
Glial Scar Prevention by RNAi
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temperature. The cells were then washed twice in PBS and
processed for immunostaining. Cells were first incubated for one
hour with a saturated 2% bovine serum albumin solution (BSA,
Sigma-Aldrich) and 0.1% Triton (Triton X-100, Sigma-Aldrich) in
PBS. They were then incubated overnight with the following
primary antibodies: (1) rabbit polyclonal IgG directed against
GFAP (1:10 000, Dako), (2) mouse monoclonal IgG directed
against GFP (AbCam, 1:500) and (3) mouse monoclonal IgM
directed against vimentin (clone IL6, 1:500, Sigma-Aldrich). All
primary antibodies were diluted in PBS supplemented with 2%
BSA and 0.1% Triton. Following incubation for 24 h at 4uC, the
cultures were rinsed with PBS and incubated for 1 hour at room
temperature with the following secondary antibodies: goat anti-
rabbit Alexa 488 (1:1000, Invitrogen), goat anti-mouse IgG Alexa
555 (1:1000, Invitrogen) and goat anti-mouse IgM Cy5 (Jackson
Immunoresearch Laboratories, Westgrove, PA). Cells were rinsed
again with PBS and incubated with Hoechst 33342 (Sigma-
Aldrich) solution for 5 minutes. Finally, the glass coverslips on
which the cells were growing were briefly rinsed in water and
mounted in Fluorescent Mounting Medium (Dako).
Analysis of neuron-glial cell cocultures, neuronal survival
and neurite outgrowth
Neuron-glial cell cocultures. Embryonic cortical neurons
were cocultured directly with transduced glial cell monolayers. A
neuronal suspension was prepared from the neocortex of 14-day-
old C57Bl/6 mouse embryos (Janvier). The meninges were
removed and the cortices were dissected in cold HBSS
containing calcium and magnesium (Gibco). The tissue was then
incubated in HBSS without calcium and magnesium for 5 minutes
at 37uC and then at 25uC. The cells were mechanically dissociated
in 1 ml of DMEM/F12 medium supplemented with N2-
complement (Gibco) and antibiotics. The cells were seeded onto
the surface of the confluent glial cell monolayers at an initial
density of 25 000 cells/well in 24-well dishes.
Neuronal survival assessment and neurite outgrowth
assay. The neuronal population was characterized by
immunocytochemistry. After 7 days in vitro in coculture, cultures
were fixed in 4% PFA in PBS. Cells were rinsed in PBS and
incubated overnight at 4uC with a mouse monoclonal IgG
antibody directed against the b-III-tubulin protein (1:500,
Sigma-Aldrich). Cells were then rinsed in PBS and incubated for
one hour with a peroxidase-conjugated rabbit anti-mouse
antibody (1:100, Sigma-Aldrich). Immunoreactivity was detected
by incubation with a substrate of peroxidase. The chromogen used
for development was 0.1% 3,39-diaminobenzidine (DAB) in the
presence of H2O2. Glass coverslips were finally mounted in Depex
after dehydration of the cells growing on them.
We measured two variables: neuronal survival and neurite
outgrowth. Neuronal survival was evaluated by measuring
neuronal density with Image J software (Cell Counting program).
Neuronal density is expressed as a percentage vs. neurons growing
on non transduced glial cell monolayers. Neurite outgrowth was
evaluated by measuring the area of the immunoreactive b-III-
tubulin occupied by the perikaria and determining the number of
neurites per neuron. Areas were measured with an automatic,
personalized threshold program, using Image J software. Three
independent experiments were performed. In each experiment,
three coverslips were used for each set of conditions, and ten fields
per coverslip were randomly selected at a magnification of x10.
Results were given as mean percentages6SEM. Statistical
comparisons were carried out for each variable using one-way
ANOVA (analysis of variance) with Bonferoni post-hoc analysis
(GraphPad Prism 5 software). Significance was accepted at
p,0.05.
Results
Identification of oligonucleotide sequences for the RNAi-
mediated inhibition of GFAP and vimentin gene
expression
The RNAi-mediated knockdown of protein expression depends
on particular oligonucleotide sequences, the efficiency of which
depends on several parameters and is specific for each animal
species. We first identified interfering sequences that allow specific
silencing of murine GFAP and vimentin. We screened the cDNAs
encoding murine GFAP and vimentin to identify oligonucleotide
sequences capable of efficiently abolishing the production of both
proteins. We chose potential siRNA sequences with selection
algorithms based on empirical criteria, as described in the
materials and methods. A panel of ten 21-nucleotide candidate
sequences was selected for each protein, at different positions
within the coding region of the corresponding mRNA (Table 1
and Table 2). BLAST analysis confirmed that none of these
sequences displayed significant sequence identity to any other
mRNA. As RNA interference triggered by shRNA constructs has
been shown to be particularly efficient, we constructed plasmid
Table 1. Candidate target sites for RNAi in mouse GFAP
transcripts.
Name siRNA sequence Position
GFAP-1 GAGCCCACCAAACTGGCTGAT 277–297
GFAP-2 GATCTATGAGGAGGAAGTTCG 560–580
GFAP-3 GAGAGAGATTCGCACTCAATA 660–680
GFAP-4 GAGAGATTCGCACTCAATACG 662–682
GFAP-5 GAGATTCGCACTCAATACGAG 664–684
GFAP-6 GCCGCCAACTGCAGGCCTTGA 812–832
GFAP-7 GCAGGAGTACCACGATCTAC 993–1012
GFAP-8 GAGATCGCCACCTACAGGAAA 1038–1058
GFAP-9 GATCGCCACCTACAGGAAATT 1040–1060
GFAP-10 GCGGGATGGTGAGGTCATTAA 1199–1219
doi:10.1371/journal.pone.0006227.t001
Table 2. Candidate target sites for RNAi in mouse Vimentin
transcripts.
Name siRNA sequence Position
VIM-1 GTGGAATCCTTGCAGGAAGAA 1150–1170
VIM-2 GAATCCTTGCAGGAAGAAATT 1153–1173
VIM-3 GAATGGTACAAGTCCAAGTTT 1345–1365
VIM-4 GATGGAAGAGAATTTTGCCCT 1518–1538
VIM-5 GTGAATACCAAGATCTGCTC 1622–1641
VIM-6 GAATACCAAGATCTGCTCAAT 1624–1644
VIM-7 GAGGAGAGCAGGATTTCTCTG 1699–1719
VIM-8 GAGAGCAGGATTTCTCTGCCT 1702–1722
VIM-9 GAACACTCCTGATTAAGACGG 1799–1819
doi:10.1371/journal.pone.0006227.t002
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vectors to express these interfering sequences as shRNAs under
control of the human U6 promoter.
We next examined the ability of the candidate sequences,
shGFAP 1 to 10, and shVIM 1 to 9, to silence production of the
GFAP-EGFP and Vim-EGFP fusion proteins, respectively. Each
candidate shGFAP or shVIM sequence was expressed from a
plasmid vector in human HEK-293 T cells cotransfected with a
plasmid encoding the GFAP-EGFP or VIM-EGFP fusion protein.
EGFP levels were determined by flow cytometry. We assessed two
variables: the overall proportion of cells expressing EGFP and
mean fluorescence intensity (MFI). Differences in the number of
EGFP-expressing cells and in MFI between cells transfected with
the different constructs reflect the extent to which the production
of GFAP-EGFP or VIM-EGFP is inhibited and, thus, the
efficiency of the GFAP- or Vim-targeting shRNAs. Two shGFAP
sequences, shGFAP-3 and shGFAP-8, significantly decreased the
number of GFAP-EGFP-positive cells by 83612.81% and
8769.4%, respectively (Fig. 1A). Moreover shGFAP-3 and sh-
GFAP-8 also reduced mean fluorescence intensity with high
significance by 9662.62% and 9663.11%, respectively (Fig. 1B).
Similarly, shVIM-3 significantly decreased the number of cells
positive for VIM-EGFP by 4561.4% (Fig. 1C). This sequence
Figure 1. Screening of shRNAs for silencing of GFAP-EGFP and Vim-EGFP fusion protein. HEK 293 T cells were cotransfected with the
GFAP-EGFP or VIM-EGFP plasmids and either pcDNA-U6wt as a control or a plasmid expressing a single shGFAP or shVIM sequence. An shRNA specific
for the EGFP mRNA (pcDNA3-U6-shEGFP) was also used as a positive control. A, C: Results are expressed as the percentage of fluorescent cells,
determined 72 h after transfection (**p,0.01, *** p,0.001, paired T-test). B, D: Results are expressed as mean fluorescence intensity, determined
72 h after transfection (**p,0.01, *** p,0.001, paired T-test).
doi:10.1371/journal.pone.0006227.g001
Glial Scar Prevention by RNAi
PLoS ONE | www.plosone.org 5 July 2009 | Volume 4 | Issue 7 | e6227
also decreased MFI by 8160.7% (Fig. 1D). Considering these
results, the two sequences shGFAP-3 and shVIM-3 were selected
for the production of lentiviral vectors.
Specific lentiviral-mediated inhibition of endogenous
GFAP and vimentin gene expression in medullar and
cortical astrocytes
GFAP and vimentin gene expression is strong and persistent in
reactive astrocytes after the occurrence of CNS lesion [43]. We
assessed the cellular effects driven by the RNAi-mediated
knockdown of GFAP and vimentin in vitro, using primary cultures
of murine astrocytes, which may be considered a model of reactive
astrocytes. The GFAP and vimentin genes were also strongly and
persistently expressed in these cultures.
The long-term, stable silencing of GFAP and vimentin in these
primary astrocyte cultures was triggered by recombinant non-
replicative lentiviral vectors expressing the selected shGFAP and
shvimentin sequences. These vectors, respectively called Lv-
shGFAP and Lv-shVIM, also encode EGFP as a reporter protein
for assessment of the transduction efficiency of the vectors. On the
same molecular basis, we also constructed vectors for the
expression of shRNA which inefficiently targeted GFAP or
vimentin. All these lentiviral vectors were pseudotyped with the
VSV envelope, which confers efficient, broad-tropism transduc-
tion in vitro [44].
The capacity of Lv-shGFAP and Lv-shVim to silence
endogenous GFAP and vimentin gene expression in vitro was
assessed by western blot analyses on cortical astrocytes. Primary
cultures of cortical glial cells were transduced with various
amounts of Lv-shGFAP, Lv-shVIM or the control vector. Two
weeks after transduction, GFAP was detected by western blotting.
Primary cultured astrocytes transduced with Lv-shGFAP vector
displayed a large, dose-dependent decrease in GFAP levels with
respect to the control vector (Fig. 2A). Western blotting showed
GFAP levels to be 70% lower than those in non transfected cells,
in cells transfected with 0.5 viral particles per cell (MOI=0.5), and
95% lower in cells transfected with 10 viral particles per cell
(Fig. 2B). Similarly, primary cultures of glial cells transduced with
the Lv-shVIM vector presented a substantial, dose-dependent
decrease in vimentin levels with respect to the control vector
(Fig. 2C). Quantitative analysis also revealed that vimentin levels
were decreased by more than 90% at an MOI of 10 (Fig. 2D).
We ascertained that the silencing of GFAP and vimentin was
due to genuine specific RNAi targeting, by comparing GFAP and
vimentin levels after the transduction of cortical glial cells with
three additional controls: (1) a lentiviral vector encoding only
EGFP under control of the PGK promoter (Lv-PGK-EGFP), (2) a
vector carrying a ‘‘scrambled’’ sequence (Lv-shRANDOM) and (3)
a vector encoding an efficient shRNA sequence targeting the leptin
receptor gene-related protein transcript OB-RGRP [45]. These
three vectors were also pseudotyped with the VSV envelope.
Cortical glial cells were transduced, as described above, with Lv-
shGFAP, Lv-shVIM and the three control vectors, at a single dose
of 10 viral particles per seeded cell. We assessed the effects of the
combinational silencing of GFAP and vimentin, by also cotrans-
ducing glial cells with both the Lv-shGFAP and Lv-shVIM vectors.
In these cultures, only glial cells transduced with Lv-shGFAP had
significantly lower levels of GFAP (Fig. 2E). Glial cells transduced
Lv-shVIM or with both Lv-shGFAP and Lv-shVIM vectors had
significantly lower levels of vimentin than non transduced cells. By
contrast, glial cells transduced with the three control vectors
presented levels of GFAP and vimentin similar to those in non
transduced cells. Interestingly, glial cells transduced with the sole
Lv-shGFAP also presents lower levels of vimentin.
In parallel, we detected GFAP and vimentin levels by
immunocytochemistry in spinal glial cell cultures after transduc-
tion with Lv-shGFAP, Lv-shVIM or the control vectors (Fig. 3).
Specific immunolabeling of GFAP and vimentin showed that Lv-
shGFAP and Lv-shVIM induced a specific and significant
decrease in GFAP and vimentin levels, respectively, in these
cultures. Moreover, as described above for cortical glial cells,
spinal glial cells cotransduced with both Lv-shGFAP and Lv-
shVIM also displayed a more pronounced decrease in the levels of
both proteins than did cells undergoing single transduction.
Altogether, both western blots of cortical glial cells and
immunocytochemical analyses of the spinal cord glial cells showed
that Lv-shGFAP and Lv-shVIM efficiently silenced endogenous
GFAP and vimentin gene expression.
GFAP and vimentin knockdown by lentiviral-mediated
RNAi decreases glial scarring in primary astrocyte
cultures
Astrocytes devoid of GFAP and vimentin present low levels of
astroglial reactivity after spinal cord hemisection in vivo [32].
Moreover, previous studies have shown that the inhibition of
GFAP production by RNA antisense methods decreases astrocyte
hypertrophy in a scratch wound model [46]. We evaluated the
functional effect of the Lv-shGFAP and Lv-shVIM vectors on the
astroglial response in vitro, by immunolabeling, to characterize the
astrocytic hypertrophy and hyperplasia of scratched primary glial
cell cultures transduced with Lv-shGFAP and Lv-shVIM.
In a first paradigm, we carried out scratch wound assays on
astrocytes previously transduced with 10 particles per cell for each
vector. The scratch was performed two weeks after transduction,
and the cells were fixed 48 hours, one week or two weeks after
scratching. At these time points, the total number of cells invading
the scratch area was evaluated by Hoechst staining. Efficiently
transduced cells were visualized by EGFP immunolabeling and
astrocytic hypertrophy was assessed by determining GFAP
immunoreactivity. We first observed invasion of the scratch area
by EGFP-positive cells in the three different control conditions
48 hours after scratching (Fig. 4A and Fig. S1A). At this time,
the lesioned area was still well outlined by GFAP staining, and
slight astrocytic hypertrophy was detected. In glial cell cultures
transduced with the Lv-shGFAP vector, total cell invasion of the
scratch area was less marked than observed for controls. In
particular, fewer EGFP-positive cells were found to be present in
the scratch area. GFAP staining also showed levels of glial
reactivity to be lower in the vicinity of the lesioned area. Similar
observations were obtained for scratched glial cell cultures
transduced with both Lv-shGFAP and Lv-shVIM. By contrast,
glial cell cultures transduced with Lv-shVIM alone displayed lower
levels of cell invasion in the scratched area, but no reduction of
GFAP staining.
One week after scratching (Fig. 4B and Fig. S1B) and two
weeks after scratching (Fig. S2A and Fig. S2B), the decrease in
size of the scratched area was much more pronounced in glial cell
cultures transduced with the control vectors. Indeed, the lesion was
barely detectable two weeks after scratching in these conditions. At
both of time points, many large EGFP-positive cells had invaded
the scratched area. These cells presented large cytoplasmic
processes, characteristic of the astrogliosis observed along the
scratch in astrocyte cultures. GFAP immunostaining also revealed
strong glial reactivity and astrocytic hypertrophy in the vicinity of
the scratched region. By contrast, in cultures transduced with Lv-
shGFAP alone or cotransduced with both Lv-shGFAP and Lv-
shVIM, astrocytes failed to repair the scratch wound, with fewer
cells invading the lesioned area, even two weeks after scratching.
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Figure 2. Knockdown of endogenous GFAP and vimentin gene expression in primary cultures of cortical astrocytes by lentiviral-
mediated RNAi. A: GFAP levels decreased in a dose-dependent manner in cultured cortical astrocytes. Astrocytes were transduced with different
amounts of the Lv-shGFAP vector one week after cell seeding. Protein levels were analyzed by western blotting 15 days after transduction with Lv-
shGFAP and were compared with those for a control vector. B: Relative quantification of GFAP knockdown. At MOI = 10, GFAP levels are decreased by
90%. C: Vimentin levels decreased in a dose-dependent manner in cultured cortical astrocytes. Astrocytes were transduced with different amounts of
Lv-shGFAP one week after cell seeding. Protein levels were analyzed by western blotting 15 days after transduction with the Lv-shVIM vector, and
were compared with those for the control vector. D: Relative quantification of vimentin knockdown. At MOI = 10, vimentin levels are decreased by
90%. E: At MOI = 10, GFAP and vimentin levels are strongly decreased in cortical astrocytes transduced with Lv-shGFAP and Lv-shVIM, respectively. By
contrast, no significant decrease in GFAP or vimentin levels was observed in astrocytes transduced with the various control vectors. Vimentin levels
were also lower in astrocytes transduced with Lv-shGFAP alone. Astrocytes were transduced with the various vectors one week after cell seeding.
Protein levels were analyzed by western blotting, 15 days after transduction.
doi:10.1371/journal.pone.0006227.g002
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Figure 3. Knockdown by lentiviral-mediated RNAi methods of endogenous GFAP and vimentin levels in primary cultures of
medullar astrocytes. GFAP and vimentin levels were decreased in medullar astrocytes transduced with Lv-shGFAP and LvshVIM, respectively. The
levels of both proteins were strongly decreased in astrocytes transduced simultaneously with Lv-shGFAP and Lv-shVIM. Astrocytes were cultured
from the spinal cords of P2 C57Bl/6 mice. The cells were infected with the Lv-PGK-EGFP, Lv-shRANDOM, Lv-shG1, Lv-shGFAP, Lv-shVIM or with both
Lv-shGFAP and Lv-shVIM, at an MOI of 10 viral particles per cell, one week after seeding. Immunostaining for perikaryon detection (Hoechst), EGFP,
GFAP and vimentin was performed two weeks after transduction. Scale bar = 50 mm.
doi:10.1371/journal.pone.0006227.g003
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Cells transduced with Lv-shGFAP alone or together with Lv-
shVIM vector were also smaller than cells transduced with the
control vectors, and had smaller cytoplasmic processes. Moreover,
GFAP immunostaining revealed astrocytic hypertrophy to be
much milder in these cultures. As previously reported, glial cell
cultures transduced with Lv-shVIM alone had an intermediate
phenotype, one and two weeks after scratching, characterized by
lower levels of cellular invasion in the scratch zone and strong
residual GFAP immunoreactivity.
In a second paradigm, we assessed the glial response in primary
cultures of astrocytes transduced with lentiviral vectors after
scratching. Two weeks after seeding, primary glial cell cultures
were scratched, and then directly transduced with the various
lentiviral vectors. Astrocytic hyperplasia and hypertrophy were
analyzed by immunolabeling, as described above. We found that,
48 hours after scratching/transduction the scratch areas and cell
morphology were similar in cells transduced with Lv-shGFAP, Lv-
shVIM or the control vectors (data not shown).
One week after scratching/transduction, scratching areas were
clearly detectable in all transduction conditions, as revealed by
Hoechst labeling of the nuclei (Fig. 5A). Nevertheless, scratched
areas in cultures transduced with the control vectors presented a
progressive invasion of EGFP-positive cells, whereas those in
cultures transduced with Lv-shGFAP and Lv-shVIM vectors did
not. Two weeks after scratching/transduction, glial cell cultures
transduced with the control vectors presented advanced wound
healing, with major colonization by EGFP-positive cells (Fig. 5B
and Fig. S3). By contrast, in glial cell cultures transduced with
Lv-shGFAP alone or together with Lv-shVIM, the scratched area
remained clearly visible, with limited wound healing. In these
cultures, GFAP immunoreactivity was also weak and limited to the
vicinity of the scratched area. Cultures transduced with Lv-shVIM
presented an intermediate phenotype, as previously described,
with stronger GFAP immunoreactivity and limited wound healing.
These results demonstrate that Lv-shGFAP, alone or in
combination with Lv-shVIM, can significantly decrease astrocyte
reactivity and glial scarring in vitro. Whether transduction of the
astrocytes precedes or is concomitant to the scratching, Lv-
shGFAP appears to modulate astroglial reactivity on both
hyperplasia and hypertrophy aspects.
GFAP and vimentin silencing by lentiviral-mediated RNAi
increases neuronal survival
We next investigated whether GFAP and/or vimentin silencing
by lentiviral-mediated RNA interference also influenced neuronal
Figure 4. Astrocytic behavior in a scratch wound assay in vitro - 1st paradigm - 48 hours and one week after the scratch wound. Cell
invasion and GFAP immunostaining are considerably reduced in the scratched area in glial cell cultures transduced with Lv-shGFAP alone or together
with Lv-shVIM 48 hours (A) or one week (B) after the scratch wound. Astrocytes were cultured from the spinal cords of P2 C57Bl/6 mice. The cells
were infected with Lv-PGK-EGFP, Lv-shRANDOM, Lv-shG1, Lv-shGFAP, Lv-shVIM or with both Lv-shGFAP and Lv-shVIM, at an MOI of 10 viral particles
per cell, one week after seeding. The scratch wound was analyzed two weeks after transduction, and immunostaining for perikaryon detection
(Hoechst), EGFP, and GFAP was performed 48 hours (A) or one week (B) after the scratch wound. Dashed lines indicate the precise location of the
scratch wound. Scale bar = 100 mm.
doi:10.1371/journal.pone.0006227.g004
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survival. In a heterotopical coculture model, we analyzed the
survival of neurons growing on astrocytes previously transduced
with Lv-shGFAP and Lv-shVIM.
We transduced primary glial cell cultures from spinal cord, as
described above, with the Lv-shGFAP, Lv-shVIM or control
vectors, using the same total amount of vector (MOI=10) in each
case. Two weeks after transduction, we seeded embryonic day-14
wild-type neocortical neurons onto the confluent spinal glial cell
cultures. b-III-tubulin-immunoreactive cells were counted after
seven days of coculture (Fig. 6). We detected no significant
difference in neuronal density between cocultures transduced with
the control vectors and non transduced cocultures. By contrast,
neuronal density appeared to be significantly higher (mean increase
of 291.61613.32% (p,0.001); 2.5 times higher) if neocortical
neurons were grown on spinal astrocytes transduced with Lv-
shGFAP. In cultures transduced with Lv-shVIM, the proportion of
b-III-tubulin-immunoreactive cells was also higher than that for
controls, by a mean of 127.72+9.17%, but this increase is
significantly different only in comparison with the cells transduced
with Lv-PGK-EGFP (p,0.05). Finally, neuronal density was even
higher in cocultures cotransduced with both Lv-shGFAP and Lv-
shVIM, at 317.67+13.43%, and this difference is extremely
significant in comparison with the four controls (p,0.001), but
not in comparison with cultures only transduced with Lv-shGFAP,
in register with previous findings with KO mice [31]
Effects of Lv-shGFAP and Lv-shVIM on axonal growth
We next investigated the effects of Lv-shGFAP and Lv-shVIM
on neurite growth, by measuring the percentage of the area
occupied per neuron in cocultures. Microscopy after b-III-tubulin
immunostaining showed that neurons presented more branching
and constituted denser neuropile when they were grown on
astrocytes transduced with Lv-shGFAP alone or cotransduced with
both Lv-shGFAP and Lv-shVIM vectors, in comparison with the
control cocultures (Fig. 7). We then quantified the area occupied
by the b-III-tubulin immunoreactive neurons growing on
astrocytes transduced with the various lentiviral vectors. For each
set of conditions, this area was expressed as a percentage, and a
value of 100% was attributed to the area occupied by neurons in
non transduced cocultures. No significant difference was detected
in the areas occupied by neurons grown on non transduced
astrocytes and neurons grown on astrocytes transduced with the
three control vectors (Fig. 8). By contrast, the immunoreactive
area occupied per neuron was significantly higher, by a mean of
Figure 5. Astrocytic behavior in a scratch wound assay in vitro - 2nd paradigm - one week and two weeks after the scratch wound.
Cell invasion and GFAP immunostaining are considerably reduced in the scratched area in glial cell cultures transduced with Lv-shGFAP alone or
together with Lv-shVIM one week (A) or two weeks (B) after the scratch wound and transduction with the lentiviral vectors. Astrocytes were cultured
from the spinal cords of P2 C57Bl/6 mice. The scratch wound was assayed two weeks after cell seeding. The cells were infected with Lv-PGK-EGFP, Lv-
shRANDOM, Lv-shG1, Lv-shGFAP, Lv-shVIM or with both Lv-shGFAP and Lv-shVIM, at an MOI of 10 viral particles per cell, directly after the scratch
wound. Immunostaining for perikaryon detection (Hoechst), EGFP, and GFAP was performed one week (A) or two weeks (B) after the scratch wound/
transduction. Dashed lines indicate the precise location of the scratch wound. Scale bar = 100 mm.
doi:10.1371/journal.pone.0006227.g005
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13865.2% (p,0.001), if neurons were grown on astrocytes
transduced with Lv-shGFAP. In cocultures transduced with Lv-
shVIM alone, the area occupied per neuron was also increased but
not significantly higher, by 118.863.73% in comparison with all
the controls. Finally, the area occupied per neuron was even
significantly higher, by a mean of 149.79% (p,0.001), in
cocultures cotransduced with both Lv-shGFAP and Lv-shVIM.
At variance, and as observed with neuronal survival assay,
statistical analysis did not reveal a significant difference in the
neuritic surface between the cells cotransduced with Lv-shGFAP
and Lv-shVIM, and cells only transduced with Lv-shGFAP.
Discussion
Several therapeutic strategies have been developed in the last
few decades to promote axonal regeneration after CNS lesions by
modifying the non permissive environment produced either by the
glial scar or by myelin debris [47]. Several of these strategies aimed
at neutralizing the inhibitory factors produced by the reactive
astrocytes, such as chondroitin sulfate proteoglycans [48,49] and
ephrins [50], or at restoring a permissive substrate for axonal
growth [51,52]. In this study, we developed an original gene
transfer strategy, making it possible to modulate the intrinsic
behavior of reactive astrocytes and to prevent glial scar formation.
Menet et al. clearly demonstrated the involvement of GFAP and
vimentin upregulation in modulating astrogliosis, in vitro and in vivo
[31,32,53]. We developed a molecular tool for targeted, post-
transcriptional GFAP and vimentin depletion, to reproduce the
physiological effects on astrogliosis and the neuronal response
observed in double-mutant animals. RNAi-mediated silencing was
efficient, thanks to two factors: i) precise oligonucleotide sequences
for triggering the RNAi pathway were identified and ii) an efficient
system was used to deliver siRNA to the targeted cells. We first
identified a shRNA sequence specific respectively for GFAP and
vimentin mRNAs, which significantly reduce the levels of the
corresponding proteins fused to the EGFP reporter protein. GFAP
and vimentin filaments have been characterized in vitro and in vivo
as polymerized structures with a half-life of eight days [54]. We
used integrative lentiviral vectors for the continuous production of
shRNAs in astrocytes, to ensure long-term inhibition of both
proteins expression. Two lentiviral vectors, Lv-shGFAP and Lv-
shVIM, were designed for the expression of the corresponding
shRNA sequences and of the EGFP reporter gene as a marker of
transduced cells. Western blot analysis showed that these vectors
induced a dose-dependent knockdown of endogenous GFAP and
vimentin gene expression in cortical glial cell cultures. Fifteen days
after transduction, the levels of both proteins were reduced by
more than 90% for a dose of 10 viral particles per cell, whereas
GFAP and vimentin levels were unaffected in cultures transduced
with three different controls. These results were confirmed with
immunocytological methods in spinal glial cell cultures. The strong
decrease in GFAP and vimentin levels in the transduced glial cells
was observed until four weeks after a single transduction,
demonstrating the stability of silencing. The lack of change in
GFAP and vimentin levels in cultures transduced with Lv-PGK-
EGFP (control 1) indicates that the strong decrease in IF proteins
level is not due to a toxic effect of the vectors. Moreover, the
specificity of RNAi-mediated GFAP and vimentin silencing was
confirmed by the lack of effect on GFAP and vimentin levels in
cultures transduced with a vector encoding a random sequence
(Lv-shRANDOM, control 2) or a vector encoding an shRNA
targeting another mRNA (Lv-shG1, control 3).
In light of these results, the efficiency of GFAP and vimentin
silencing by lentiviral-mediated RNAi methods may be considered
similar to that for other posttranscriptional silencing strategies
targeting one or both of these proteins. Two major approaches to
reduce GFAP expression have been developed. Eng et al., using a
retrovirus-based delivery method and then Lefranc¸ois et al., using
Lipofectamine, demonstrated that GFAP production could be
inhibited by antisense RNA in primary cultures of astrocytes
[46,55]. Eng et al. observed a qualitative decrease in GFAP levels
on immunocytochemistry, resulting in a clear decrease in
astrocytic hypertrophy [46]. Lefrancois et al. showed, by
immunoprecipitation, that the efficiency of GFAP inhibition with
antisense RNA was about 20 to 30%. Nevertheless, none of these
studies reported cellular effects induced by the antisense RNA-
mediated inhibition of GFAP beyond 72 hours, and it is therefore
difficult to assess the stability of the inhibition achieved with these
approaches. Rozovsky et al. manipulated GFAP gene expression in
rat astrocytes, using a non viral method to deliver RNAi sequences
[56]. This resulted in a 30% decrease in the total number of cells
producing GFAP. Thus, our approach using vector-based RNAi is
currently the most powerful tool for the stable and efficient
reduction of endogenous GFAP and vimentin gene expression.
We assessed the cellular effects of the RNAi-mediated silencing
of GFAP and vimentin on glial reactivity and neuron-glia
interactions. We first analyzed the consequences of the decrease
in GFAP and vimentin levels for the scarring process. The ability
of Lv-shGFAP and Lv-shVIM to modulate astroglial hypertrophy
and hyperplasia was evaluated in a ‘‘scratch wound assay’’ in
primary astrocyte cultures. This cellular model is widely used for
investigations of the involvement of molecular factors, such as
Figure 6. Cortical neuronal survival on cultured medullar
astrocytes transduced with the Lv-shGFAP and Lv-shVIM
vectors. Quantification of b-III-tubulin-positive cells per square
millimeter cocultured on astrocyte monolayers transduced with the
various control vectors, Lv-shGFAP, Lv-shVIM, or with both Lv-shGFAP
and Lv-shVIM, at an MOI of 10 viral particles per cell. Note the
significantly higher survival for neurons growing on astrocytes
transduced with Lv-shGFAP alone or with both Lv-shGFAP and Lv-
shVIM (***p,0.001, one way ANOVA with Bonferoni post hoc test).
doi:10.1371/journal.pone.0006227.g006
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Figure 7. Immunocytochemical characterization of cocultured neurons on astrocyte monolayers transduced with Lv-shGFAP and
Lv-shVIM. Neurons were immunocytochemically characterized by b-III-tubulin detection. A high density of b-III-tubulin-positive neurons with a
complex network can be observed on astrocytes transduced with the Lv-shGFAP vector or cotransduced with both Lv-shGFAP (E) and Lv-shVIM (G),
and, to a lesser extent, on astrocytes transduced with Lv-shVIM alone (F). By contrast, a low density of neurons with few neurite extensions is
observed on non transduced astrocytes (A) or on astrocytes transduced with the following control vectors: Lv-PGK-EGFP (B), Lv-shRANDOM (C) and
Lv-shG1 (D). Scale bar = 100 mm.
doi:10.1371/journal.pone.0006227.g007
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Eph4A [50], tenascin-C [57], Rho GTPase [58] or even GFAP
[46] in the glial reactivity. We used this cellular model in two
different paradigms. In the first paradigm, we studied the behavior
of scratched astrocytes which were previously transduced with Lv-
shGFAP and Lv-shVIM. We found that astrocytes transduced
with Lv-shGFAP alone or together with Lv-shVIM displayed
lower levels of cell invasion of the scratched area and a reduced
astrocytic hypertrophy than cultures transduced with control
vectors. By contrast, astrocytes transduced with Lv-shVIM alone
presented an intermediate phenotype, with a reduction of cell
invasion and a persistent glial hypertrophy.
The cellular response of transduced astrocytes was then assessed
in a different set of experimental conditions, in which astrocytes
were transduced after the scratching assay. This paradigm
reproduces more closely the conditions of a therapeutic approach.
In these conditions, we found that Lv-shGFAP alone, or together
with Lv-shVIM, decreased astrocytic hypertrophy and cellular
invasion of the lesioned area. These results confirm and extent those
obtained by Eng. et al at 72 hours with antisense RNA, for later time
points. Indeed, the results obtained in the second paradigm indicate
that the RNAi silencing process has the same cellular effects on glial
hypertrophy and cell colonization when induced after the ‘‘lesion’’.
Neuronal survival and neurite growth are two key elements of
axonal regeneration after a lesion. We investigated whether
decreasing GFAP and vimentin levels by lentiviral-mediated RNAi
methods could influence neuron-glia interactions, as described for
GFAP knockout and GFAP/Vim double-knockout mice [31]. We
showed, in a heterotopic coculture model, that Lv-shGFAP, but
not Lv-shVIM, had significant neurotrophic and neuritogenic
effects. Considering both neuronal survival and neurite growth,
the effects observed with Lv-shGFAP used alone were similar with
those observed with the combination of Lv-shGFAP with Lv-
shVIM. These results confirm the relationship between astrocytic
GFAP inhibition and increases in neuronal plasticity, as previously
reported for KO mice.
Quantitative analyses also showed that cotransduction with Lv-
shGFAP and Lv-shVIM did not significantly increase neuronal
survival or neurite growth in comparison with single transduction
with Lv-shGFAP, by contrast with the results obtained with
transgenic mice. These observations may be explained by the
intrinsic differences between the transgenesis and RNAi-mediated
silencing processes. In terms of cellular and molecular dynamics,
brisk RNAi-silencing could not generate the progressive compen-
satory phenomenon observed in GFAP 2/2 or Vim 2/2 mice,
particularly as the IFs GFAP and vimentin form copolymers. This
hypothesis is consistent with the biochemical analysis of endoge-
nous GFAP and vimentin gene expression after RNAi silencing.
We found that transduction with Lv-shGFAP alone led to a
decrease in vimentin levels. As the RNAi sequence targeting
GFAP does not match the sequence of vimentin mRNA, this effect
cannot be due to non specific side effects of RNAi. Our results
strongly suggest that, in adults, GFAP is the key modulator in the
structural assembly of GFAP/Vim polymers. These results are in
accordance with the previous studies on transgenic mice [59,60]
which establish that GFAP is the necessary protein, instead of
vimentin, for the formation of normal intermediate filaments in
astrocytes. Moreover our observations remain consistent, at the
functional level, with our previous studies revealing that GFAP is
the key modulator of astroglial reactivity [31,32].
These results indicate that GFAP is a major target to modify
astroglial reactivity and consequently neuron-glia interactions for
therapeutic purposes. Precisely, monitoring GFAP levels through
the use of lentiviral vectors appears as a powerful approach to an
efficient reduction of scarring after lesion formation and
promotion of both neuronal survival and neuritogenesis.
In conclusion, our in vitro findings indicate that Lv-shGFAP,
alone or in combination with Lv-shVIM, constitutes a powerful
molecular tool for limiting astrocyte reactivity and promoting
axonal plasticity. This study provides the necessary proof-of-
principle that the manipulation of reactive astrocytes with Lv-
shGFAP can be used to stimulate axonal regeneration in the
injured CNS. In the perspective of a potential therapeutic use, this
strategy is appropriate for an application in animal models of CNS
injury. The intrinsic properties of lentiviral vectors make them
particularly suitable for gene transfer into the CNS [44]. Sustained
transgene expression, even after cell division, is essential for the
manipulation of astroglial reactivity, which involves a significant
rate of cell multiplication. The possibility of pseudotyping lentiviral
vectors to target astrocytes is also a considerable advantage [61].
Thus, the application of Lv-shGFAP and Lv-shVIM in mouse
models of spinal cord injury would be of particular relevance for
studying in vivo the effects of these vectors on glial scar formation
and axonal regeneration. Moreover, these tools can be of value for
adjunct therapy in several CNS pathological conditions, such as
Parkinson disease, in which astrocyte reactivity is an impediment
to spontaneous axonal plasticity [62].
Supporting Information
Figure S1 Astrocytic behavior in a scratch wound assay
in vitro - 1st paradigm - two weeks after the scratch
wound. Cell invasion and GFAP immunostaining are consider-
Figure 8. Cortical neurite growth on cultured medullar
astrocytes transduced with Lv-shGFAP and Lv-shVIM. Quantifi-
cation of the percentage of the area occupied per b-III-tubulin-positive
cell on astrocyte monolayers transduced with the various control
vectors, Lv-shGFAP, Lv-shVIM, or both Lv-shGFAP and Lv-shVIM, at an
MOI of 10 viral particles per cell. Greater neurite growth is observed if
neurons are cocultured with astrocytes transduced with Lv-shGFAP or
with both Lv-shGFAP and Lv-shVIM (***p,0.001, one way ANOVA with
Bonferoni post hoc test).
doi:10.1371/journal.pone.0006227.g008
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ably reduced in the scratched area in glial cell cultures transduced
with Lv-shGFAP alone or together with Lv-shVIM two weeks after
the scratch wound. Astrocytes were cultured from the spinal cords
of P2 C57Bl/6 mice. The cells were infected with Lv-PGK-EGFP,
Lv-shRANDOM, Lv-shG1, Lv-shGFAP, Lv-shVIM or with both
Lv-shGFAP and Lv-shVIM, at an MOI of 10 viral particles per
cell, one week after seeding. The scratch wound was analyzed two
weeks after transduction, and immunostaining for perikaryon
detection (Hoechst), EGFP, and GFAP was performed two weeks
after the scratch wound. Dashed lines indicate the precise location
of the scratch wound. Scale bar = 100 mm.
Found at: doi:10.1371/journal.pone.0006227.s001 (9.51 MB TIF)
Figure S2 Astrocytic behavior in a scratch wound assay
in vitro - 1st paradigm. Cell invasion and GFAP immuno-
staining are considerably reduced in the scratched area in glial cell
cultures transduced with Lv-shGFAP alone or together with Lv-
shVIM 48 hours (A), one week (B) or two weeks (C) after the
scratch wound. Astrocytes were cultured from the spinal cords of
P2 C57Bl/6 mice. The cells were infected with Lv-PGK-EGFP,
Lv-shRANDOM, Lv-shG1, Lv-shGFAP, Lv-shVIM or with both
Lv-shGFAP and Lv-shVIM, at an MOI of 10 viral particles per
cell, one week after seeding. The scratch wound was analyzed two
weeks after transduction, and immunostaining for perikaryon
detection (Hoechst), EGFP, and GFAP was performed 48 hours
(A), one week (B) or two weeks (C) after the scratch wound.
Dashed lines indicate the precise location of the scratch wound.
Scale bar = 50 mm.
Found at: doi:10.1371/journal.pone.0006227.s002 (6.00 MB TIF)
Figure S3 Astrocytic behavior in a scratch wound assay
in vitro - 2nd paradigm - two weeks after the scratch
wound. Cell invasion and GFAP immunostaining are consider-
ably reduced in the scratched area in glial cell cultures transduced
with Lv-shGFAP alone or together with Lv-shVIM two weeks after
the scratch wound and transduction with the lentiviral vectors.
Astrocytes were cultured from the spinal cords of P2 C57Bl/6
mice. The scratch wound was assayed two weeks after cell seeding.
The cells were infected with Lv-PGK-EGFP, Lv-shRANDOM,
Lv-shG1, Lv-shGFAP, Lv-shVIM or with both Lv-shGFAP and
Lv-shVIM, at an MOI of 10 viral particles per cell, directly after
the scratch wound. Immunostaining for perikaryon detection
(Hoechst), EGFP, and GFAP was performed two weeks after the
scratch wound/transduction. Dashed lines indicate the precise
location of the scratch wound. Scale bar = 50 mm.
Found at: doi:10.1371/journal.pone.0006227.s003 (8.76 MB TIF)
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